Form D · Biotechnology
Rani Therapeutics Holdings, Inc.
San Jose, CA · CIK 0001856725
Offering snapshot reported Nov 10, 2025 · SEC filing
- Reported sold
- $60.3M Offering amount: $60.3M
- Investors reported
- 15 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 23, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 10, 2025 | Initial | $60,255,052 | No comparison | 15 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $2.95M
- Finders' fees
- $0
- Form D file number
- 021-563500
Includes pre-payment of the aggregate exercise price of $2,870.00 for pre-funded warrants and $6,000,000.00 in debt conversion.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co, LLC | 375 | |
| Maxim Group LLC | 120708 |
Source: Form D, filed Nov 10, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Dennis Ausiello | Director |
| Vasudev Bailey, M.D. | Director |
| Abraham Bassan | Director |
| Jean Luc Butel | Director |
| Mir Hashim | Executive |
| Talat Imran | Director, Executive |
| Mir Imran | Director |
| Lisa Rometty | Director |
| Svai Sanford | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2051 Ringwood Avenue
San Jose, CA, 95131
San Jose, CA, 95131